Mosquito-transmitted Sindbis virus (SINV) causes fever, skin lesions and musculoskeletal symptoms if transmitted to man. SINV is the prototype virus of genus Alphavirus, which includes other arthritogenic viruses such as chikungunya virus (CHIKV) and Ross River virus (RRV) that cause large epidemics with a considerable public health burden. Until now the human B-cell epitopes have been studied for CHIKV and RRV, but not for SINV. To identify the B-cell epitopes in SINV-infection, we synthetised a library of linear 18-mer peptides covering the structural polyprotein of SINV, and probed it with SINV IgG-positive and IgG-negative serum pools. By comparing the binding profiles of the pools, we identified 15 peptides that were strongly reactive only with the SINV IgG-positive pools. We then utilized alanine scanning and individual (n=22) patient sera to further narrow the number of common B-cell epitopes to six. These epitopes locate to the capsid, E2, E1 and to a region in PE2 (uncleaved E3-E2), which may only be present in immature virions. By sequence comparison, we observed that one of the capsid protein epitopes shares six identical amino acids with macrophage migration inhibitory factor (MIF) receptor, which is linked to inflammatory diseases and to molecular pathology of alphaviral arthritides. Our results add to the current understanding on SINV disease and raise questions of a potential role of uncleaved PE2 and the MIF receptor (CD74) mimotope in human SINV infection.
INTRODUCTION
Sindbis virus (SINV) is a mosquito-transmitted zoonotic human pathogen that is widely distributed among wildlife, especially birds, in Eurasia, Africa, Australia and Oceania (Adouchief et al., 2016) . SINV causes clinical disease mainly in Northern Europe and South Africa, where outbreaks have occurred in a cyclic manner (at 5-10-year intervals) (Brummer-Korvenkontio et al., 2002; Uejio et al., 2012) , similarly to many other arboviruses. The regular occurrence of human disease in restricted regions, despite the wide geographical distribution of SINV, is hypothesized to be due to ecology, human genetics, differences between virus strains and/or low clinical alert in most areas (Jalava et al., 2013; Lundström & Pfeffer, 2010; Sane et al., 2012; Uejio et al., 2012) .
SINV belongs to the genus Alphavirus in the family Togaviridae (International Committee on Taxonomy of Viruses, 2014) . The SINV genome is single-stranded positive sense RNA of approximately 11 700 nt, and it encodes four non-structural (nsP1-4) and five structural proteins (C, E3, E2, 6K and E1) (Strauss & Strauss, 1994) . The virion comprises an icosahedral nucleocapsid, a host-derived lipid membrane and a protein shell of trimers of E1-E2 heterodimers (Strauss & Strauss, 1994) . Initially, the structural polyprotein is synthesized from subgenomic 26S mRNA. The capsid protein is released from the polyprotein by autocleavage in the cytosol, while the host cell's signal peptidase cleaves PE2 (the precursor of E3 and E2), 6K and E1 from each other in the rough endoplasmic reticulum (rER) (Strauss & Strauss, 1994) . PE2 and E1 then form heterodimers, which are processed and transported to the plasma membrane in secretory vesicles (Erwin & Brown, 1980; Rice & Strauss, 1982) . At a late stage of the secretory pathway, PE2 is cleaved by the host cell's furin-like protease to yield E3 and E2 (de Curtis & Simons, 1988) . The maturation includes also glycosylation of Asn139 and Asn245 in E1 and of Asn196 and Asn318 in E2 (Mayne et al., 1985) .
In humans, SINV-induced disease presents as rash (88-100 %), fever (23-80 %) and debilitating musculoskeletal manifestations (93-100 %) that persist in approximately 25 % of patients for over 3 years (Adouchief et al., 2016; Kurkela et al., 2008a) . Ankles, wrists and the joints of hands are typically affected bilaterally (Sane et al., 2011) . Patients develop a strong antibody response within 11 days post infection (p.i.) as detected by increase in the levels of IgM, IgG1 and IgG3 (Kurkela et al., 2005; Manni et al., 2008; Vene et al., 1994) . The IgM response may occasionally persist for years (Niklasson et al., 1988) . However, a correlation between serological parameters and disease severity has not been established. Persistent SINV-induced disease is speculated to be partially mediated by autoimmune reaction. For instance, the levels of antinuclear and antimitochondrial antibodies, and rheumatoid factor are elevated among patients as compared to reference population (Sane et al., 2012) . In support of autoimmune reaction, the persisting musculoskeletal symptoms after SINVinduced disease have been associated with HLA DRB1*01 haplotype of the MHC system (Sane et al., 2012) . The same HLA haplotype is also linked to other diseases with joint symptoms, such as rheumatoid arthritis (Weyand et al., 1992) and acute human parvovirus infection (Kerr et al., 2002) .
Other arthritogenic alphaviruses such as chikungunya virus (CHIKV) and Ross River virus (RRV) share similarities with SINV in their clinical manifestations, epidemiology and pathogenesis (Suhrbier et al., 2012) . Especially, CHIKV has widely been studied due to epidemic emergence in countries around the Indian Ocean and the Caribbean and in Central and South America (Fischer et al., 2014) . The humoral immune response plays also a key role in the recovery from CHIKV infection (Kam et al., 2012a) . Quite recently, a linear epitope highly reactive with patient but not with healthy control plasma was identified in the N-terminal part of CHIKV E2 (Kam et al., 2012a, b) . Immunization of mice with the corresponding peptide resulted in reduced virus titres and less severe joint symptoms in subsequent experimental infection (Kam et al., 2012b) . SINV has been utilized as a model when studying viruses of the genus Alphavirus, and as an example of an encephalitiscausing virus in mice (Griffin et al., 1997) . A prominent epitope region has been mapped to amino acids 181-220 of E2 utilizing murine monoclonal antibody escape mutants (Davis et al., 1987; Mendoza et al., 1988; Meyer & Johnston, 1993; Olmsted et al., 1986; Strauss et al., 1991) , but to our knowledge the exact epitope regions in human SINV infection have not been mapped to peptide level. We have previously shown by Western blotting that both SINV E1 and E2 are targets of human immune response (Manni et al., 2008) .
The main objective of this study was to identify and map human B-cell epitopes of SINV structural proteins. Further, we wanted to study whether the differences in the epitopes recognized or antibody maturation patterns would correlate with the severity of symptoms and/or clinical outcome. An overlapping peptide library was used for this purpose. The identified epitopes were estimated for their antigenicity, surface accessibility and sequence homology with human proteome in order to study potential for molecular mimicry and putative autoimmunity triggering.
RESULTS
Epitope mapping of SINV structural proteins with patient sera
The structural proteins of SINV (strain Ilomantsi 2002-A) were synthesized as a library of 247 membrane-bound 18-mer peptides with an overlap of five amino acids. The membrane was probed with a serum pool from SINVnatïve humans and, thereafter, with a serum pool from patients with confirmed SINV infection. Antibody binding to individual peptides was recorded on X-ray film utilizing enhanced chemiluminescence and the films were evaluated by both densitometric scanning and visual evaluation. As expected, the probing with patient as compared to SINVnatïve serum pool resulted in more of the peptides being reactive (Fig. 1) .
Five of the most reactive peptides located to the capsid (C-P1 to C-P5), three to E2 (E2-P2, -P3 and -P4), six to E1 (E1-P1 to P6) and one to the junction of E3 and E2 (E3E2-P1). This region of PE2 (non-cleaved E3-E2) is in vivo cleaved by furin during virus maturation. Curiously, the adjacent peptides were found to be non-reactive. To further study the reactivity at this region, we included two additional peptides -the C-terminus of E3 (E3-P1), and the N-terminus of E2 (E2-P1) -in the subsequent analyses (Table 1) .
Fine mapping of the amino acids critical for antigenicity
Alanine scanning was used to identify the amino acids that are critical for antibody binding, and to further verify the reactivity of the identified epitopes. The new library was probed with sera of individual patients to increase specificity of the findings. Six of the selected 17 peptides were found to react strongly with the majority of the serum samples (18-21 of 21 patients) in the alanine scanning: C-P1, C-P2, E3E2-P1, E2-P3, E2-P4 and E1-P5. Four of the peptides (C-P3, C-P5, E1-P4 and E1-P6) showed intermediate binding frequency being reactive with 9-15 of the 21 patient sera, while the rest were recognized by a few sera only. Curiously, both E3-P1 and E2-P1, which flank the stronglyreacting furin cleavage site E3E2-P1, remained non-reactive. Amino acids critical for the reactivity were identified in E2E3-P1, E2-P3, E2-P4 and in E1-P5 (Fig. 2) . In E3E2-P1 alteration of Arg5 or Arg8, both located in the E3 part of the peptide, reduced the reactivity. E2-P3 contained a stretch of critical amino acids from Glu7 to Leu15, and the replacement of either Ile11 or Leu13 resulted in complete loss of reactivity. In E2-P4, the important residues were found to be Gly6 and Lys7. Also E1-P5 contained several amino acids that were found to be crucial for antibody binding: Asp3, Leu4, Ser7, Asp9, Ile10, Arg11 and Leu12.
Correlation of peptide reactivity to the clinical outcome and temporal differences in epitope reactivity
To determine if the patients with different clinical outcome of SINV infection would recognize a different set of epitopes, we used serum samples collected from patients of a prospective cohort recruited during a disease outbreak caused by SINV infection (Kurkela et al., 2008a) . The serum samples of the cohort were collected at four time points: (1) early acute phase (median 3 days post symptom onset, A linear 18-mer peptide library was produced and probed with pooled patient sera. A total of 15 peptides were recognized as strongly reactive for most patient pools. In order to more closely investigate the furin cleavage site between E3 and E2, two additional peptides were synthetised for the subsequent alanine exchange experiments (one at the N-terminus of E3 and one at the C-terminus of E2). In the original reactive peptide, the change of E3 to E2 is indicated by bold type text font of the amino acid sequence. In C-P1 the protein BLAST tool recognized a stretch of six amino acids identical with CD74, with a total score of 23.5 and E-value of 11. The amino acid sequence MLGRRP shared with CD74 is highlighted in bold font.
Protein Peptide name First amino acid Last amino acid Sequence
, (2) late acute phase (median 10 d.p.s.), (3) convalescent phase (6 months p.i.) and (4) follow-up medical examination (3 years p.i.). The patients were grouped based on evaluation by a rheumatologist 3 years p.i. into three distinct categories: objectively arthritic/arthralgic, subjectively arthralgic and fully recovered (Kurkela et al., 2008a) .
Serum pools of acute phase samples collected in median 10 d.p.s. were used to evaluate the reactivity to the abovementioned peptides. Serum pools were used for this purpose to increase sensitivity, and to identify the dominant epitopes. The patients that fully recovered from SINV infection (n=10) displayed antibodies against fewer epitopes (a) Fig. 2 . Epitope fine mapping using alanine scanning. We used the sera of individual patients to analyse the importance of individual amino acids for the reactivity of the 15 selected peptides. The reactivity of each peptide with an alanine change was scaled by naked eye into four categories ('no binding' to 'strong reactivity') and the mean reactivity strength of these individual peptides was calculated. (a) Reactivity patterns of individual patients (y-axis) and the colour-coded binding intensity for each amino acid substituted by alanine. Darker grey denotes stronger reactivity. Peptides C-P1, C-P2, E3E2-P1, E2-P3, E2-P3 and E1-P5 were reactive with 18-21 of 21. (b) Importance of individual amino acids for antibody recognition. Mean reactivity of a given peptide with alanine exchange was compared to the reactivity of the parent peptide as percentage of mean parent peptide reactivity. Presented are those six peptides that reacted both strongly and commonly in the alanine scanning. Amino acids important for antigenicity are circled.
(antibodies to 9/17 epitopes) as compared to the patients with prolonged symptoms (n=12, 15/17 epitopes; Fisher's exact P=0.03). All patient groups reacted with peptides CP-1, C-P3, C-P4, E2-P2, E2-P3, E1-P2 and E1-P3 (Table 2a) . Peptides reactive with a given serum pool as determined by combining the densitometric quantification and 'naked eye' verification were judged as positive, while the non-reactive were considered negative. Serum pools of acute samples from patients with persistent musculoskeletal symptoms 3 years p.i. (objective or subjective) were reactive against four peptides, E2E3-P1, E2-P4, E1P4 and E1-P5, that were not recognized by the serum pool of fully recovered patients. Individual serum samples collected at 6 months p.i. were used in the subsequent alanine scanning. The differences in the epitope patterns identified in the alanine scanning were less pronounced between the patients with different clinical outcomes when studying the samples collected at 6 months p.i. (Fig. 2a , Table S1 , available in the online Supplementary Material). A correlation between epitope reactivity at 6 months p.i. and clinical outcome was evident only in E1-P4 which was reactive with 7/10 patients with eventual full recovery and merely 2/11 patients with some form of chronic manifestation at 3 years p.i. (Fisher's exact test P=0.0299).
To assess the potential chronologic changes in the spectrum of epitopes recognized, pooled sera of patients with objective arthralgia 3 years p.i. (n=5) were examined at four time points (Table 2b ). Antibodies to C-P1, C-P3, E3E2-P1, E2-P23 and E2-P3 were detectable at all time points. The early acute serum pool reacted additionally with C-P2 and E2-P4, while the late acute (10 d.p.s.) and the convalescent (6 months p.i.) phase sera pools additionally recognized E1-P1, E1-P2, E1-P3 and E1-P5. To conclude, a higher variety and stronger reactivity towards most epitopes was observed in serum pools of the fully initiated acute phase (10 d.p.s.) and the convalescent phase (6 months p.i.) as compared to the reactivity of the hyper-acute and chronic phase serum pools. Reactivity (%) Reactivity (%) In silico analysis of the biochemical properties of the identified peptide epitopes Finally, freely available biochemical prediction tools were used to evaluate whether the epitopes could have been identified by in silico analysis. The Kolaskar and Tongonkar antigenicity prediction tool estimated four of the six identified epitopes as probable (C-P2, E3E2-P1 ending, E2-P3 and E1-P5), while an epitope prediction tool (ABCpred) identified all of the peptides identified in our study as potentially antigenic sites (Table 3 ). The surface accessibilities of the identified epitopes were also examined by visualizing the location of the peptides in the 3D structure of E1-E2 heterodimers (Fig. 3) . The identified peptides were further analysed by prediction tools for peptide flexibility, hydrophobicity, hydrophilicity and surface accessibility probability as summarized in Table 3 .
Since autoimmune reactions have been suggested to contribute to the aetiology of SINV-induced disease (Sane et al., 2012) , potential molecular mimicry of host proteins by the identified epitopes was evaluated by BLAST-search (Table 1) . Intriguingly the amino-terminal peptide, C-P1, of SINV capsid protein (aa 1-18) contained a stretch of six consecutive amino acid residues (M8, L9, G10, R11, R12 and P13) identical to macrophage migration inhibitory factor (MIF) receptor, CD74 (296 amino acids total).
DISCUSSION
In this report we describe for the first time human B-cell epitopes and study how the epitope pattern changes during the course of SINV infection. For this study, we utilized a unique cohort of patients followed up to 3 years p.i. and overlapping synthetic membrane-bound 18-mer peptides (i.e. PepSpot method) covering the structural polyprotein of an epidemic wild-type SINV strain isolated in Finland (Ilomantsi 2002-A) . PepSpot is designed mainly to detect 'linear' epitopes formed of consecutive amino acids; however, due to the very high local concentration of peptides it is also possible that some conformational epitopes can be detected. Using the above-mentioned approach we identified six common (reactive with 18-21 out of 21 samples tested) epitopes. Of the six epitopes, one had an interesting sequence similarity with MIF receptor CD74, and one Table 2 . Evaluation of patient antibody responses Patient sera were pooled and examined with a linear peptide library in PepSpot. The antibody binding strength was measured in OD units using Chemidox and confirmed by visual examination where false-positive results were rejected. Here, the reactivity of each serum pool with the 15 peptides selected for further analyses and the two additional peptides synthetised adjacent to the E3-E2 junction (E3-P1 and E2-P1) are marked as + or -according to epitope identification capability. Strong binding of peptide by a serum pool is indicated by +. (a) Visualization of differences in reactive peptides between patient groups with different clinical outcomes. Serum samples from patients were drawn at median 10 days after symptom onset. The patient cohort was examined by a rheumatologist 3 years p.i. and divided into four categories. Here we included patients that were objectively arthralgic or arthritic (categories A+B, n=7), subjectively arthralgic (category B, n=5) and fully recovered (category C, n=10). Reactivity of pooled sera 10 d.p.s. with given peptides. (b) Antibody affinity maturation among patients with persistent symptoms (n=5). Patient plasma samples were taken twice during acute phase (median 3 d.p.s. and median 10 d.p.s.), during convalescent phase at 6 months p.i. and during a clinical check-up at 3 years p.i. Reactivity of pooled sera from patients with objective arthralgia at 3 years p.i.; n=5 
located to a furin cleavage site. The rest had no specific findings in our experiments or remarks in the literature.
Two of the identified epitopes, C-P1 and C-P2 (amino acids 1-18 and 46-63), locate to the capsid protein (264 amino acids). Both of the regions were also evaluated as potential epitopes by an epitope prediction algorithm and antigenicity prediction tool. Correspondingly, for CHIKV a stretch of 37 amino acids located at the N-terminus of the capsid protein has been recognized as highly antigenic (Goh et al., 2015) . One of the epitopes identified, E3E2-P1, located to the junction of E3 and E2, which is cleaved by furin during virion maturation process. The epitope is formed of amino acids 56-63 of E3 and 1-10 of E2, and is located to a region in E2 that is surface accessible in the crystallographic structures of the mature virion, but was not considered highly antigenic according to the prediction tools used. Intriguingly, the peptides located adjacent to E3E2-P1 remained non-reactive in all experiments, denoting a possible role for immature virions containing non-cleaved PE2 in the B-cell response towards SINV infection. Additionally, three of the identified epitopes locate to the glycoprotein spike complex. The E2-P3 (residues 273-290) and E2-P4 (308-325) of E2
and E1-P5 (209-226) of E1 are all surface accessible on the SINV structure. The E2-P3 and E1-P5 locate to regions that are antigenic by prediction, whereas E2-P4 and E1-P5 were considered potential epitopes by the epitope prediction software used. The epitope region located to amino acids 180-220 of E2, identified in mouse model studies, was not found reactive in our patient-sample-based study.
In general, the characterization of viral epitopes is beneficial for designing diagnostic tools, and for therapy and vaccine development. The epitopes we identified may be applicable for serodiagnostic purposes. At the moment the serodiagnosis of SINV infection usually requires two consecutive serum samples taken at least 1 week apart (Manni et al., 2008) . Furthermore, SINV is ill recognized in non-endemic regions and on the other hand often diagnosed without proper laboratory verification in the endemic regions (Brummer-Korvenkontio et al., 2002; Kurkela et al., 2004) . A rapid, robust, simple, inexpensive peptide-based diagnostic test would potentially ease the serodiagnosis and would likely increase the proportion of confirmed cases. A similar diagnostic approach has also been considered for CHIKV (Kam et al., 2015) . Peptide-based vaccines are currently
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Nucleocapsid Nucleocapsid Nucleocapsid Nucleocapsid Fig. 3 . Location of the identified epitopes on the E2-E1 heterodimer. Presented is a schematic viral membrane with an attached capsid-glycoprotein dimer complex. The capsid resides within the viroplasm, both E1 and E2 glycoproteins have elongated structures protruding through the viral membrane and their glycosylated main portions form the viral envelope. Capsid proteins form an icosahedron under the membrane with tightly attached E2-E1 glycoprotein spikes protruding. Epitopes E3E2-P1, E2-P3, E2-P4 and E1-P5 are highlighted on the surface structures of SINV. Structures are derived from PDB (code 3J0F), and the images were generated using YASARA. The other identified epitopes C-P1 and C-P2 were unplottable on the available structures.
extensively studied as an attractive alternative to conventional vaccines due to the specificity of the elicited immune response (Li et al., 2014) , as also implied for CHIKV (Kam et al., 2014) . Currently, there is no specific treatment for Table 3 . Summary of computationally predicted biochemical characteristics of the six identified epitopes For C-P1 the protein BLAST result of amino acid sequence similarity with MIF receptor, also known as CD74, is highlighted by grey background colour. For E2E3-P1, E2-P3, E2-P4 and E1-P5, the amino acids necessary for reactivity in alanine scanning are marked. Epitope E2-P4 contains an N-linked glycosylation site, which is marked. 
N Alanine scanning (necessary amino acids) G K Emini surface accessibility scale Flexibility (Karplus and Schulz)
SINV-induced disease, which albeit usually short in duration, does persist in approximately 25 % of patients for at least 3 years (Kurkela et al., 2008a; Niklasson & Espmark, 1986) . Due to the persistent symptoms, SINV is a public health concern in endemic regions, wherein the SINV seroprevalence can reach 10 % (Kurkela et al., 2008b) . For CHIKV, which causes a similar although often more severe disease, the search for potential antivirals is active (Abdelnabi et al., 2015) . Indeed, for CHIKV, treatment with monoclonal antibodies derived from patients, non-human primates or mouse serum has shown potential for protecting mice from infection challenge (Fric et al., 2013; Goh et al., 2013; Kam et al., 2012b; Pal et al., 2013; Selvarajah et al., 2013; Smith et al., 2015) .
The epitopes identified in this study were also evaluated for sequence similarities to human proteome. Sequence identity of six consecutive amino acids was identified between C-P1 and MHC II invariant chain, also known as CD74. Hypothetically, such mimotopes could be involved in the triggering of autoimmune reactions via molecular mimicry. However, this identical hexapeptide locates to the cytoplasmic part of CD74, which makes it less likely that the antibodies would react against cell surface CD74 molecules. On the other hand, CD74 has a rapid turnover of just 10 min (Moldenhauer et al., 1999) , which may increase the possibility of the cytosolic part being transiently exposed to the extracellular milieu. Anti-CD74 antibodies have been shown to increase the activity and longevity of B-cells (Starlets et al., 2006) , and thus binding of anti-SINV antibodies to CD74 through molecular mimicry could have similar effects. In general, CD74 functions as a chaperone by blocking unwanted peptide binding to MCH type II, but approximately 5 % of the CD74 population is found on the cell surface, where CD74 serves as a receptor for MIF (Stumptner-Cuvelette & Benaroch, 2002; Wraight et al., 1990) . MIF has been linked to many diseases with an inflammatory component, including atherosclerosis, kidney diseases and rheumatoid arthritis (Bernhagen et al., 2007; Morand & Leech, 2005; Valiño-Rivas et al., 2015) . MIF has also been shown to increase leucocyte proliferation, chemotaxis and survival as well as the production of inflammatory cytokines, and antibodies (Bacher et al., 1996; Bernhagen et al., 2007; Gore et al., 2008; Marsh et al., 2009; Starlets et al., 2006) . On the basis of the murine model of RRV disease, MIF and CD74 may play significant roles in diseases caused by arthritogenic alphaviruses (Herrero et al., 2011 (Herrero et al., , 2013 . In the case of SINV infection, primary human macrophages cause a significant increase in the production of MIF during an in vitro infection challenge (Assunção-Miranda et al., 2010) . Therefore, further investigations are warranted on the potential molecular mimicry between SINV C-P1 and CD74.
Intriguingly, a peptide at the junction of E3 and E2 reacted strongly with antibodies in patient sera, while peptides corresponding to either the C-terminus of E3 or N-terminus of E2 remained non-reactive. In comparison, the prominent epitope described for CHIKV locates in the 18 N-terminal amino acids of E2 (Kam et al., 2012a) . Furthermore, antibodies against this epitope were found in the acute phase sera of the patients that developed persistent symptoms. By 6 months p.i., both the completely recovered and symptomatic patients had antibodies against this epitope, suggesting that the kinetics of antibody production against SINV E2EP3 epitope might differ between these groups.
Normally during an alphavirus infection the capsid protein, PE2, 6K and E1 are cleaved from the viral structural polyprotein in cytosol and rER. E1 and PE2 then form heterodimers at the Golgi apparatus (Watson et al., 1991) . PE2 (i.e. uncleaved E3/E2) remains intact during vesicle transport protecting the E2-E1 heterodimer spikes from premature activation in the acidic environment (Uchime et al., 2013) . PE2 is cleaved by furin in the late stages of the secretory pathway prior to glycoprotein shell formation (de Curtis & Simons, 1988; Watson et al., 1991) . The cleavage then allows the structural changes leading to a smooth-surfaced lattice on the icosahedral virion surface as opposed to the more 'spiky' surface of the protruding spikes of the immature particle. In some cases, however, immature glycoprotein spike heterodimers are incorporated into the virion (Russell et al., 1989; Ryman et al., 2004) . Immature particles have been described also in other virus families, for instance during dengue virus infections, the immature particles have been shown to play a role in the pathogenesis (RodenhuisZybert et al., 2010) . Adaptation of SINV to baby hamster kidney (BHK) cells was reported to occur via PE2-E1 incorporation into the virion after a mutation of either S1R, E70L or S114R in E2 (Klimstra et al., 1998 (Klimstra et al., , 1999 . The mutation S1R also creates a new glycosylation site (Russell et al., 1989) . The uncleaved PE2-E1 facilitates attachment to heparan sulfate on target cell surfaces, but lowers infectivity (Klimstra et al., 1999) . The significance of E3E2-P1 and PE2 for SINV infection and its clinical consequences as well as the potential use of the identified epitope in serodiagnostics are interesting topics for further studies.
METHODS
Patient samples and controls. The serum samples included in the study are from a prospective cohort of patients recruited during a disease outbreak caused by SINV infection. The cohort has been studied prospectively in 2002-2005 and the characteristics of the patients have been described previously (Kurkela et al., 2005 (Kurkela et al., , 2008a . An ethics statement applying also to this work was obtained from the Hospital District of Helsinki and Uusimaa (HUS Central Ethical Committee, permission number 127/13/03/00/2009).
The serum panel included four consecutive samples for most patients. Two of the samples were taken during the acute phase of the disease, median 3 and 10 d.p.s. The acute phase samples were initially used as paired serum samples for disease diagnosis, which was made after a positive IgM result and a fourfold or greater increase in IgG titre between paired sera or a positive IgM result and a negative/borderline IgG result (which excludes old immunity) with a specific reaction in haemagglutination test. The third sample was obtained at the convalescent phase, 6 months p.i. and the fourth sample 3 years p.i.. All samples were stored at À20 C. Serum samples from SINV-negative patients stored at À20 C were used as controls.
Quality of life was monitored in two questionnaires: at 1 and 3 years p.i.. The patients were also examined by a rheumatologist 3 years after the acute infection and the patients were divided into four categories according to the clinical outcome at 3 years p.i.. Two patients with arthritis of small joints formed group A, five patients with objective arthralgia group B, five patients with reported joint pains that were unconfirmed by a rheumatologist group C and 35 patients with complete recovery group D. In this study, we included all patients with symptoms in the medical examination 3 years p.i. (groups A-C, 12 patients) and ten randomly selected patients from the fully recovered patient group D.
Peptide synthesis and Spot assay. The structural proteins of SINV (strain Ilomantsi 2002-A (I6QL65), isolated from mosquitoes in the endemic Pohjois-Karjala province during an outbreak in 2002) were synthesized as a library of 247 linear 18-mer peptides with an overlap of five amino acids with PepSpot technique, as described previously (Hepojoki et al., 2010b) . In the PepSpot technique, a high density of peptides is synthetised on modified cellulose membranes forming a meshwork of the produced peptides. The probing of the membrane with pooled sera and individual serum samples was done as described previously (Kuivanen et al., 2014) . The method is best suited for recognition of linear epitopes, but has been reported in some cases to detect conformational epitopes as well (Heiskanen et al., 1999; Hepojoki et al., 2010a; Li et al., 2016 ).
The peptide library was probed with patient sera organized in pools according to clinical outcome of the infection. We also probed the library with pools of sera withdrawn at different time points after infection and disease onset.
Densitometric and visual analysis of binding strength. The antibody binding to individual peptides was evaluated in two steps: initial analysis was done by densitometric scanning of the membrane after recording the result on X-ray film (Fuji Medical RX) and the secondary analysis by visual inspection. Peptides recognized by SINV-negative sera were excluded from further studies.
The densitometric analysis was performed using Chemidoc XRS (BioRad). The obtained intensity values were used for evaluating the binding strengths of individual peptides. The densitometric analysis was found to provide a good comparison of binding strengths of different peptides to antibodies of a single serum or serum pool examined, but the method could not be used to compare the binding strengths of peptides between different sera or serum pool probes. To normalize the probings with different sera samples, we measured the OD values of all peptides and selected the strongly binding peptides by comparing the obtained intensity value (peptide OD divided by mean background OD) to a probespecific threshold value [defined as average backgrond OD + (3*standard deviation)]. The reactivities of individual peptides were further graded into non-reactive, weak, reactive or strongly reactive by naked eye. Peptides selected by densitometry were rejected if they showed weak or no reactivity in the visual examination in at least two-thirds of the examined sera or if they were identified by sera from SINV-natïve persons.
Protein structures. The identified epitopes were plotted on SINV structural proteins using YASARA (Krieger & Vriend, 2014 ; http://www. yasara.org/). Structure of SINV virion containing glycoproteins E1 and E2 and the capsid protein was obtained from Protein Data Bank (PDB code 3J0F) (Tang et al., 2011) . The epitopes were highlighted both on individual proteins as well as on the heterodimer spike.
Computational predictions. We used open access algorithms to evaluate and predict certain functional aspects of the SINV structural polyprotein. Kolaskar and Tongaonkar antigenicity scale was used for evaluating antigenicity (Kolaskar & Tongaonkar, 1990) , ABCpred for linear epitope prediction (Saha & Raghava, 2006) , Emini for surface accessibility (Emini et al., 1985) , Karplus and Schulz for flexibility (Karplus & Schulz, 1985) and Parker for hydrophilicity (Parker et al., 1986 ).
NCBI's Basic Local Alignment Search Tool for protein structures (pr-BLAST) was used to look for sequence homology between the identified six peptide epitopes and human proteome.
